77P A real-world population study in early breast cancer to identify patient characteristics, treatment and outcomes in Scotland

Abstract

Despite adjuvant endocrine treatment (AET) advances, hormone receptor positive (HR+), human epidermal growth factor receptor 2-negative (HER2−), node-positive early breast cancer (EBC) is associated with a considerable (∼20%) risk of recurrence. We conducted a retrospective study to describe demographic/clinical characteristics and outcomes alongside treatment patterns in patients (pts) with HR+, HER2− node-positive EBC in the region of Scotland served by the Edinburgh Cancer Centre, a specialist referral centre.